Squarepoint’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Squarepoint’s Portfolio LABD Stock Details LABD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07M	Buy	+65,713	New	+$1.24M	﹤0.01%	2721
2024 Q4	–	Sell	-8,722	Closed	-$534K	–	5295
2024 Q3	$509K	Buy	+8,722	New	+$530K	﹤0.01%	3074
2024 Q2	–	Sell	-10,060	Closed	-$733K	–	4385
2024 Q1	$733K	Buy	+10,060	New	+$839K	﹤0.01%	2803
2023 Q3	–	Sell	-4,735	Closed	-$680K	–	4039
2023 Q2	$680K	Buy	+4,735	New	+$707K	﹤0.01%	2438
2022 Q3	–	Sell	-4,226	Closed	-$1.65M	–	3220
2022 Q2	$1.65M	Buy	+4,226	New	+$2.12M	0.01%	1310
2021 Q4	–	Sell	-1,703	Closed	-$363K	–	3359
2021 Q3	$363K	Buy	+1,703	New	+$362K	﹤0.01%	2154

Other funds holding LABD

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

CCM

Capstone Capital Management Hong Kong $224M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Squarepoint's LABD Position: Q1 2026 in Review

Squarepoint opened a new position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2026: 65,713 shares worth $1.07M. The stake represents ﹤0.01% of the portfolio and ranks #2721 among its holdings. This is a return to the name: Squarepoint previously reported a position in LABD as recently as Q3 2024.

Squarepoint first reported a position in LABD in Q3 2021 and has held it in 6 quarters since. The position peaked at $1.65M in Q2 2022. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

Squarepoint held 65,713 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $1.07M as of Q1 2026.
Direxion Daily S&P Biotech Bear 3X ETF was a new Squarepoint position in Q1 2026.
Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2721 holding.
Squarepoint first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q3 2021 and has held it in 6 quarters since.
Squarepoint's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $1.65M in Q2 2022.
17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.